



UNIVERSITÀ  
POLITECNICA  
DELLE MARCHE

## RESEARCH AREA: VIRUS

---

**TITLE:** Tofacitinib versus standard of care in patients with early onset SARS-CoV2 (COVID-19) interstitial pneumonia: a multicenter randomized controlled open label trial

**Principal investigator:** Prof. Armando Gabrielli, [a.gabrielli@staff.univpm.it](mailto:a.gabrielli@staff.univpm.it), tel:[071 220 6104](tel:0712206104)

**UNIVPM Research Group:** DISCLIMO, Clinica Medica

**Research activity description:** We investigate the efficacy of Tofacitinib, an anti Jak 1-3 drug ) in patients with early onset SARS-CoV2 (COVID-19) interstitial pneumonia. Link Submitted to AIFA for approval

**Collaborators:** Azienda Ospedaliero-Universitaria Ospedali Riuniti, Ancona

---